D&D PHARMATECH
D&D Pharmatech is a operator of a holding company created to fund the development of therapeutic medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. The company's product pipeline focuses on a range of indications including neurodegenerative, metabolic and fibrotic diseases, providing the opportunity to accelerate the translation of cutting-edge research into lifesaving therapeutic products for patients.
D&D PHARMATECH
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2014-01-01
Status:
Active
Total Funding:
224.1 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Apache Mobile Non Scaleable Content Google Apps For Business Google Maps Google Maps API Sectigo SSL
Similar Organizations
FAB Pharmaceuticals
FAB Pharmaceuticals is a Health Care Company.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
Pearl Care
Pearl Care is Healthcare company.
Pharmate
Pharmate is a health care company.
StanPlus
A Health And Healthcare Company.
Trinomab
Trinomab is a Healthcare company.
Current Employees Featured
Founder
Investors List
DS Asset Management
DS Asset Management investment in Series C - D&D Pharmatech
Praxis Capital Partners
Praxis Capital Partners investment in Series C - D&D Pharmatech
Korea Investment Securities
Korea Investment Securities investment in Series C - D&D Pharmatech
Kudos Venture Capital
Kudos Venture Capital investment in Series C - D&D Pharmatech
Magna Investment
Magna Investment investment in Series B - D&D Pharmatech
InterVest Co.
InterVest Co. investment in Series B - D&D Pharmatech
Octave Life Sciences
Octave Life Sciences investment in Series B - D&D Pharmatech
LB Investment
LB Investment investment in Series B - D&D Pharmatech
Smilegate Investment
Smilegate Investment investment in Series B - D&D Pharmatech
LB Investment
LB Investment investment in Series A - D&D Pharmatech
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2018-07-18 | Neuraly | D&D Pharmatech investment in Series A - Neuraly | 36 M USD |
More informations about "D&D Pharmatech" on Search Engine
D&D Pharmatech Raises $51M in Series C Financing to …
Oct 19, 2021 D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies …See details»
D&D Pharmatech Granted Fast Track Designation from US FDA …
Apr 2, 2024 GYEONGGI-DO, South Korea & GAITHERSBURG, Md., April 02, 2024 -- ( BUSINESS WIRE )--D&D Pharmatech, Inc. (D&D), a clinical-stage biotechnology …See details»
D&D Pharmatech Company Profile - Craft
Healthcare - Private. Compare competitors. D&D Pharmatech has 5 employees across 2 locations and $155.61 m in total funding,. See insights on D&D Pharmatech including …See details»
Culturally Nimble CEO Ready to Lead D&D Pharmatech
Published: Jul 06, 2021 By Gail Dutton. Yoo-Seok Hong, CEO of D&D Pharmatech, pictured above. Yoo-Seok Hong, the newly-appointed CEO of D&D Pharmatech, has moved between South Korea and North America …See details»
D&D Pharmatech Announces Agreement with Salubris …
Sep 27, 2021 D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier...See details»
Ahead of IPO, D&D Pharmatech wins US fast track for MASH drug
Apr 4, 2024 Ahead of IPO, D&D Pharmatech wins US fast track for MASH drug. April 4, 2024. By Marian (YoonJee) Chu. Building D&D Pharmatech Inc. has been a …See details»
D&D Pharmatech Announces First Patient Dosed in …
Mar 30, 2021 D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies …See details»
D&D Pharmatech Raises $51M in Series C Financing to Advance …
Oct 19, 2021 GYEONGGI-DO, Korea & GAITHERSBURG, Md.– D&D Pharmatech Inc., a clinical-stage biotechnology company focused on development and commercialization of …See details»
D&D Pharmatech closes $51M series C round, eyes Seoul IPO
Oct. 19, 2021. By Cormac Sheridan. D&D Pharmatech Inc., a Korean-American firm commercializing innovation from Johns Hopkins University raised $51 million in a pre …See details»
D&D bags $137M to fund midphase Alzheimer's, Parkinson's trials
Aug 14, 2019 D&D Pharmatech has raised $137.1 million to advance treatments for neurodegenerative diseases and fibrosis. The series B will enable one D&D subsidiary …See details»
D&D Pharmatech Granted Fast Track Designation from US FDA …
Apr 2, 2024 D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies …See details»
D&D Pharma snags $51M ahead of Korean IPO for Alzheimer's, …
By Kyle LaHucik Oct 19, 2021 7:00am. Alzheimer's funding nonalcoholic steatohepatitis (NASH) Parkinson's disease. D&D Pharmatech has secured $51 million to fund clinical …See details»
D&D Pharmatech Company Profile 2024: Stock Performance
Jul 18, 2018 Description. D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, …See details»
D&D Pharmatech Announces Rapid, Clinically Significant
May 2, 2023 D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies …See details»
D&D Pharmatech | CipherBio
D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and …See details»
D&D Pharmatech Announces Rapid, Clinically Significant …
02-May-2023. D&D Pharmatech Announces Rapid, Clinically Significant Reductions in Liver Fat Achieved in Four Weeks Treating NAFLD Patients with DD01, a Novel Long …See details»
D&D Pharmatech Granted Fast Track Designation from US FDA …
April 3, 2024 checkorphan. GYEONGGI-DO, South Korea & GAITHERSBURG, Md. — D&D Pharmatech, Inc. (D&D), a clinical-stage biotechnology company focused on the …See details»
D&D Pharmatech - Raised $205M Funding from 11 investors
May 4, 2024 $205M. $137M in Largest Round. Investors. 11 Institutional. D&D Pharmatech Funding. How much funding did D&D Pharmatech raise in its latest …See details»
D&D Pharmatech - Company Profile - Tracxn
May 4, 2024 Founded Year. 2018. Location. Seongnam-si, South Korea. Company Stage. Series C. Total Funding. $205M. Latest Funding Round. $51M, Series C, Oct 19, 2021. …See details»
DD 01 - AdisInsight - Springer
Apr 4, 2024 At a glance. Originator D and D Pharmatech. Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Peptides. Mechanism of Action Glucagon like …See details»